Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 13, Issue 4, Pages 395-411Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728220902841045
Keywords
addiction; Alzheimer's disease; audition; cardiovascular dysfunction; epilepsy; immune system; ligand gated channel; neuromuscular junction; nicotinic acetylcholine receptors; pain; Parkinson's disease; schizophrenia; skin; therapeutic treatments; alpha 4 beta 2; alpha 6; alpha 7
Categories
Ask authors/readers for more resources
Background: Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels that participate in many physiological functions. Receptors result from the assembly of five homologous or heterologous subunits that form the ligand-binding site and an ionic pore. In vertebrates, 17 subunits have been identified, alpha (1 - 10), beta (1 - 4), gamma, delta and epsilon. Assembly of different subunit combinations allows a diversity of physiological and pharmacological properties. Objective: To review the putative involvement of nAChRs in several diseases. Methods: We discuss the expression pattern of the subunits, the pharmacological tools for distinguishing them and their role in pathogenesis. Results/conclusion: Long-standing efforts in this field should soon result in the finding of new molecules that might be applicable to situations ranging from neurological diseases to immune treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available